![]() Pembrolizumab, a humanized monoclonal antibody against programmed death 1 (PD-1), promotes T cell-mediated antitumor activity by inhibiting the interaction between PD-1 and its ligands, programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2). Keywordsįive Year Lung Cancer Survival Update Introduction Our findings confirm pembrolizumab as a standard-of-care treatment in the second-line or later setting. Pembrolizumab continued to provide long-term benefit than docetaxel in patients with previously treated advanced NSCLC with PD-L1 TPS ≥50% and ≥1%. ![]() Five Year Lung Cancer Survival Update Conclusions Exploratory biomarker analysis revealed that higher tissue tumor mutational burden (≥175 mutations per exome) was associated with improved outcomes with pembrolizumab. A total of 21 patients received second-course pembrolizumab 11 (52.4%) had an objective response after starting the second course and 15 (71.4%) were alive at data cutoff. Among 79 patients who completed 35 cycles/2 years of pembrolizumab, the OS rate 3 years after completion (∼5 y from randomization) was 83.0%. The 5-year OS rates for pembrolizumab versus docetaxel were 25.0% versus 8.2% in patients with PD-L1 TPS ≥50% and 15.6% versus 6.5% with PD-L1 TPS ≥1%. Median study follow-up was 67.4 months (range: 60.0‒77.9). Five Year Lung Cancer Survival Update ResultsĪ total of 1034 patients were randomized (pembrolizumab, n = 691 docetaxel, n = 343). Pembrolizumab doses were pooled in this analysis. Patients who completed pembrolizumab treatment and subsequently had recurrence could receive second-course pembrolizumab for up to 17 cycles (1 y). Patients were randomized to pembrolizumab 2 mg/kg or 10 mg/kg once every 3 weeks or docetaxel 75 mg/m 2 once every 3 weeks for up to 35 cycles (2 y). Five Year Lung Cancer Survival Update Methods We report 5-year efficacy and safety follow-up for the KEYNOTE-010 study. In the KEYNOTE-010 study, pembrolizumab improved overall survival (OS) versus docetaxel in patients with previously treated, advanced NSCLC with programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) ≥50% and ≥1%. From Journal of Thoracic Oncology Five Year Lung Cancer Survival Update Introductionįive year lung cancer survival update based on clinical trial data.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |